IQVIA Holdings Inc. (NYSE:IQV) Holdings Cut by Trillium Asset Management LLC

Trillium Asset Management LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 97,324 shares of the medical research company’s stock after selling 5,043 shares during the quarter. Trillium Asset Management LLC owned approximately 0.05% of IQVIA worth $24,612,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. AdvisorNet Financial Inc boosted its stake in IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the period. Rise Advisors LLC bought a new position in IQVIA in the 1st quarter worth approximately $31,000. BKM Wealth Management LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $32,000. Riverview Trust Co bought a new stake in IQVIA during the 1st quarter valued at $32,000. Finally, Activest Wealth Management acquired a new position in IQVIA during the 4th quarter worth $35,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Barclays cut their price objective on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. Evercore ISI reduced their price target on shares of IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Robert W. Baird dropped their target price on IQVIA from $241.00 to $235.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Truist Financial decreased their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $255.73.

IQVIA Trading Down 0.1 %

Shares of IQVIA stock traded down $0.28 during trading on Friday, hitting $224.57. The stock had a trading volume of 1,066,345 shares, compared to its average volume of 1,065,908. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The company has a market capitalization of $40.92 billion, a PE ratio of 30.46, a P/E/G ratio of 2.10 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The stock has a 50 day simple moving average of $219.73 and a 200 day simple moving average of $228.90.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.11. The firm had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.